Opportunity
SAM #75N98026Q00782
Sole Source Procurement of Custom MHC Class II HLA-DP Xynapse and Dextramer Reagents for Liver Cancer Research
Buyer
NIH Office of Logistics and Acquisition Operations
Posted
July 14, 2026
Respond By
July 22, 2026
Identifier
75N98026Q00782
NAICS
325414, 325413, 813920
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is seeking to procure specialized immunological research reagents for liver cancer neoantigen validation. - Government Buyer: - National Cancer Institute (NCI), NIH, Department of Health and Human Services - OEM Highlight: - Immudex USA, LLC / Immudex ApS is the sole source and manufacturer of the required reagents - Products/Services Requested: - Custom MHC Class II HLA-DP Xynapse and Dextramer reagents - Used specifically for liver cancer neoantigen validation research - No part numbers or quantities specified in the available documentation - Unique/Notable Requirements: - Immudex is the only provider with the proprietary technology and manufacturing capability for these reagents - The government has prior positive experience with Immudex products and considers no other source capable of meeting the technical requirements - All technical and product details are proprietary to Immudex and not available from other sources
Description
Custom MHC Class II HLA-DP Xynapse and Dextramer Reagents for Liver Cancer Neoantigen Validation